ALKAbello AS ALK B Financial and Strategic SWOT Analysis Review [Report Updated: 14032018] Prices from USD $125

02:04 EDT 8 Apr 2018 | BioPortfolio Reports

ALKAbello AS ALK B Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.


The profile contains critical company information including:


Business description A detailed description of the company's operations and business divisions.

Corporate strategy Analyst's summarization of the company's business strategy.

SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history Progression of key events associated with the company.

Major products and services A list of major products, services and brands of the company.

Key competitors A list of key competitors to the company.

Key employees A list of the key executives of the company.

Executive biographies A brief summary of the executives' employment history.

Key operational heads A list of personnel heading key departments/functions.

Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


Highlights


ALKAbello AS ALK, a subsidiary of The Lundbeck Foundation discovers, develops and commercializes immunotherapies for allergy prevention and treatment. It markets diagnostics and other services to allergy clinics. The company's allergy immunotherapy product portfolio includes tabletbased vaccines, sublingual or dropbased vaccines, subcutaneous vaccines; and adrenaline autoinjector to treat severe allergic reactions in emergencies anaphylaxis. ALK's research and development pipeline products include sublingual immunotherapy tablets for addressing the ragweed, house dust mite and tree pollen allergy. The company's products target allergies caused by grass, tree, ragweed, house dust mite, Japanese cedar, dog, venom and cat, among others. It has subsidiaries in Europe, North America, AsiaPacific and other international markets. ALK is headquartered in Horsholm, Denmark.


ALKAbello AS Key Recent Developments


Feb 06,2018: ALK releases its annual report 2017

Nov 29,2017: Management change at ALK

Nov 10,2017: ALKAbello: Ninemonth interim report Q3 2017

Nov 03,2017: ALK appoints Soren Jelert as new Chief Financial Officer

Sep 21,2017: ALK acts on French injunction by accelerating investments in its quality system at the French manufacturing facility


Key benefits of buying this profile include:


You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.


Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.


Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.


Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.


Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.


Note: Some sections may be missing if data is unavailable for the company

Original Article: ALKAbello AS ALK B Financial and Strategic SWOT Analysis Review [Report Updated: 14032018] Prices from USD $125

More From BioPortfolio on "ALKAbello AS ALK B Financial and Strategic SWOT Analysis Review [Report Updated: 14032018] Prices from USD $125"